
news +insights
Eli Lilly Lehigh Valley Plant: $3.5 Billion Obesity Drug Site Breaks Ground

Construction is now underway on the Eli Lilly Lehigh Valley plant, a $3.5 billion injectable medicine and device facility in Fogelsville, Pennsylvania, after the company held its groundbreaking on November 12, 2026 (Eli Lilly and Company). This is an update to our earlier coverage of Lilly’s U.S. manufacturing push: the Pennsylvania site moves from announced plan to active jobsite, with 2,000 construction jobs expected during the build and operations targeted for 2031.
What Happened
Lilly broke ground on the facility in Upper Macungie Township, in Pennsylvania’s Lehigh Valley, and said the plant will manufacture injectable medicines including retatrutide, an investigational once-weekly drug that acts on the GIP, GLP-1 and glucagon receptors (Eli Lilly and Company). The site is one of 10 new U.S. manufacturing sites Lilly has announced since 2020 and one of four in that group dedicated to injectables and devices (Eli Lilly and Company).
The company expects the plant to support 850 permanent jobs for engineers, scientists, operations staff and lab technicians, and about 2,000 construction jobs while the site is built and brought online (Eli Lilly and Company). BioProcess International reported the same 850 permanent and roughly 2,000 construction positions and noted that Chair and CEO Dave Ricks attended the event with local leaders (BioProcess International).
Ricks said in the release that “Obesity is one of the biggest health challenges of our time,” and that the investment will let Lilly make these medicines in Pennsylvania for patients in the U.S. and abroad (Eli Lilly and Company). He told the crowd that “this will be an export site for Lilly,” according to Pharma Manufacturing (Pharma Manufacturing).
Pennsylvania Gov. Josh Shapiro called the event “another historic milestone in Pennsylvania’s thriving life sciences sector,” and U.S. Sen. Dave McCormick described the investment as “another major win for Pennsylvania” (Eli Lilly and Company).
How the Site Was Chosen
Lilly first unveiled the Lehigh Valley project in a January 30 announcement, saying it had reviewed more than 300 applications before selecting Fogelsville for its proximity to STEM universities, its technical manufacturing economy and its existing infrastructure (Fierce Pharma). Fogelsville sits about 11 miles from Allentown, in a region once known for steel and heavy manufacturing (Fierce Pharma).
The plant completed the set of four U.S. plants Lilly promised under a $27 billion pledge, alongside sites in Virginia, Texas and Alabama (Fierce Pharma). Lilly says it has invested more than $50 billion in U.S. manufacturing expansion since 2020 (Fierce Pharma). The Pennsylvania groundbreaking followed Lilly’s Goochland County, Virginia groundbreaking, which we covered in Update: Lilly Breaks Ground on $5B Richmond-Area Drug Plant, and a Houston groundbreaking weeks earlier for an oral GLP-1 manufacturing site (BioProcess International).
Where Things Stand
Lilly’s full map of new U.S. sites since 2020 includes five active pharmaceutical ingredient plants (Richmond, Virginia; Huntsville, Alabama; Houston, Texas; and two in Lebanon, Indiana), four injectables and devices sites (Research Triangle Park and Concord, North Carolina; Kenosha, Wisconsin; and the Lehigh Valley), and one genetic medicines site in Lebanon, Indiana (Eli Lilly and Company).
The Lehigh Valley design leans heavily on automation. Lilly says the site will use machine learning, AI, digitally integrated systems and advanced data analytics, with digital automation built in throughout operations, and it is targeting LEED Gold certification (Eli Lilly and Company). Site head Roberto Vázquez Sanabria said, “The goal is to have a fully automated process from receiving materials through the warehouse” (Pharma Manufacturing).
Lilly also described its current quality controls as more than 5,000 documented steps per production run, with each unit inspected more than 70 times for defects (Eli Lilly and Company). Dan VonDielingen, senior vice president of global parenteral network expansion, said earlier this year that Lilly is standardizing its new sites using lessons from existing plants and contract manufacturers (Pharma Manufacturing).
On the community side, Lilly will provide up to $1 million over five years to a quality-of-life program at the Upper Macungie Community Center, focused on nutrition, fresh food access and health resources (Eli Lilly and Company).
One caution on the product: retatrutide remains in multiple Phase 3 trials and is not approved for sale (Eli Lilly and Company).
Implications for Owners, Developers, Contractors and Subs
- A long build window. With operations targeted for 2031, the Eli Lilly Lehigh Valley plant points to several years of work for site, structural, process piping, cleanroom and commissioning trades in eastern Pennsylvania (Eli Lilly and Company).
- Automation-heavy scope. A plan for full automation from material receipt through the warehouse means controls integration, robotics and data infrastructure will be a large share of the scope, not an add-on (Pharma Manufacturing).
- Sustainability documentation. A LEED Gold target brings material tracking, commissioning and documentation requirements that subcontractors should price in (Eli Lilly and Company).
- Labor competition. About 2,000 construction workers on one project will draw on the regional trades pool at the same time other pharma campuses are moving forward, a trend we tracked in Pharma Campus Wave: Five U.S. Drug Plant Projects Total $13.15 Billion.
What to Watch
- Announcements of the general contractor, design team and major trade packages, which none of the sources named.
- Progress on retatrutide’s Phase 3 trials, since the plant’s first named product is still investigational (Eli Lilly and Company).
- Hiring pace, as Lilly says it is already recruiting for the site (Eli Lilly and Company).
Bottom Line
The $3.5 billion Fogelsville plant is now a live construction project, not just a pledge. With 2,000 construction jobs, a 2031 operations target and a design built around automation and LEED Gold, it is one of the larger private industrial builds in the Northeast, and part of a national run of pharma plants that is keeping specialized trades busy (Eli Lilly and Company).
Key Questions
Where is the Eli Lilly Lehigh Valley plant located?
The plant is in Fogelsville, within Upper Macungie Township in Pennsylvania’s Lehigh Valley (Eli Lilly and Company).
How much is Lilly investing in the Lehigh Valley site?
Eli Lilly is investing $3.5 billion in the Lehigh Valley injectable medicine and device facility, which broke ground on November 12, 2026 (Eli Lilly and Company).
How many jobs will the Lilly Fogelsville plant create?
Lilly expects 850 permanent jobs at the Fogelsville site and about 2,000 construction jobs during the build (Eli Lilly and Company).
When will the Lilly Lehigh Valley plant open?
Lilly expects the Lehigh Valley plant to be operational by 2031 (Eli Lilly and Company).
What will the Lilly Pennsylvania plant make?
The Pennsylvania plant will make injectable medicines, including retatrutide, an investigational obesity drug still in Phase 3 trials (Eli Lilly and Company).
Related Coverage
- Update: Lilly Breaks Ground on $5B Richmond-Area Drug Plant
- Pharma Campus Wave: Five U.S. Drug Plant Projects Total $13.15 Billion
- Pharma’s $480 Billion U.S. Construction Wave: What Onshoring Means for Builders and Owners
Image credit: Eli Lilly and Company. Image from the source article, Eli Lilly and Company.
Sources
- Eli Lilly and Company, “Lilly breaks ground in Pennsylvania’s Lehigh Valley on a $3.5 billion site to make next-generation obesity medicines, the latest of 10 new U.S. sites since 2020,” https://investor.lilly.com/node/55301
- Pharma Manufacturing, “Eli Lilly breaks ground on $3.5B Pennsylvania site for next-generation obesity medicines,” https://www.pharmamanufacturing.com/facilities/facility-design-management/article/55418695/eli-lilly-breaks-ground-on-35b-pennsylvania-site-for-next-generation-obesity-medicines
- BioProcess International, “Lilly breaks ground on $3.5bn manufacturing site in Pennsylvania,” https://www.bioprocessintl.com/facilities-capacity/lilly-breaks-ground-on-3-5bn-manufacturing-site-in-pennsylvania
- Fierce Pharma, “Lilly rounds out quartet of new US plants with $3.5B injectable and device facility in Pa.,” https://www.fiercepharma.com/pharma/lilly-rounds-out-quartet-new-us-plants-35b-injectables-and-device-facility-pa






